Shaji K. Kumar, MD, is a Consultant in the Division of Hematology and Mark and Judy Mullins Professor of Hematological Malignancies at Mayo Clinic in Rochester, Minnesota. He is the Chair of the Myeloma, Amyloidosis, and Dysproteinemia Disease Group at Mayo Clinic, Research Chair for the Division of Hematology, and Associate Chair for Research in the Department of Medicine. 
Dr. Kumar received his medical degree from the All India Institute of Medical Sciences in New Delhi, India. His postdoctoral training included a residency in Internal Medicine from the All India Institute of Medical Sciences, followed by an Internal Medicine residency and a hematology/oncology fellowship at the Mayo Graduate School of Medicine in Rochester, Minnesota. He then completed a Mayo Foundation Scholar at the Dana Farber Cancer Institute in Boston. 
Dr. Kumar’s research focuses on the development of novel drugs and drug combinations for the treatment of myeloma. He is the Principal Investigator of several phase 1, 2, and 3 clinical trials. He also focuses on the mechanisms of disease progression from precursor conditions and risk stratification of plasma cell disorders. His laboratory focuses on understanding the role of the bone marrow microenvironment in the development and progression of myeloma.Dr. Kumar serves as Co-Chair of the NCI Myeloma Steering Committee and as Chair of the NCCN Multiple Myeloma Guidelines Panel. He is the President-Elect of the International Society of Amyloidosis and the Treasurer of the International Myeloma Society. He is the Editor in Chief of The Hematologist.
Dr. Kumar has been associated with Binaytara Foundation for over a decade, educating cancer care providers at BTF’s CME accredited hematology oncology conferences in different parts of the country.